F. Papa

Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit

R. Ferrigno, M. D. De Martino, R. Patalano, 2019, Scientific Reports.

mTOR Inhibitor Use Is Associated With a Favorable Outcome of COVID-19 in Patients of Kidney Transplant: Results of a Retrospective Study

F. Salemi, F. Crocetto, R. La Rocca, 2022, Frontiers in Medicine.

The role of mTOR pathway as target for treatment in adrenocortical cancer

M. D. De Martino, L. Hofland, C. Simeoli, 2019, Endocrine connections.

The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center

R. Ferrigno, M. D. De Martino, A. Colao, 2019, Journal of endocrinological investigation.

GH deficiency in cancer survivors in the transition age: diagnosis and therapy

A. Isidori, A. Grossman, E. Sbardella, 2020, Pituitary.